Literature DB >> 33468245

Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis.

Ricardo da Cruz Lage1, Claudia Diniz Lopes Marques2, Thauana Luiza Oliveira3, Gustavo Gomes Resende4, Charles Lubianca Kohem5, Carla Gonçalves Saad6, Antônio Carlos Ximenes7, Célio Roberto Gonçalves6, Washington Alves Bianchi8, Eduardo de Souza Meirelles6, Mauro Waldemar Keiserman9, Adriano Chiereghin10, Cristiano Barbosa Campanholo11, André Marun Lyrio12, Cláudia Goldenstein Schainberg6, Lenise Brandao Pieruccetti13, Michel Alexandre Yazbek14, Penelope Esther Palominos5, Rafaela Silva Guimarães Goncalves2, Rodrigo Luppino Assad15, Rubens Bonfiglioli12, Sônia Maria Alvarenga Anti Loduca Lima16, Sueli Carneiro17, Valderílio Feijó Azevedo18, Cleandro Pires Albuquerque19, Wanderley Marques Bernardo6, Percival Degrava Sampaio-Barros6, Marcelo de Medeiros Pinheiro3.   

Abstract

Spondyloarthritis (SpA) is a group of chronic inflammatory systemic diseases characterized by axial and/or peripheral joints inflammation, as well as extra-articular manifestations. Over some decades, nonsteroidal anti-inflammatory drugs (NSAIDs) have been the basis for the pharmacological treatment of patients with axial spondyloarthritis (axSpA). However, the emergence of the immunobiologic agents brought up the discussion about the role of NSAIDs in the management of these patients. The objective of this guideline is to provide recommendations for the use of NSAIDs for the treatment of axSpA. A panel of experts from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis of randomized clinical trials for 15 predefined questions. The Grading of Recommendations, Assessment, Development and Evaluation methodology to assess the quality of evidence and formulate recommendations were used, and at least 70% agreement of the voting panel was needed. Fourteen recommendations for the use of NSAIDs in the treatment of patients with axSpA were elaborated. The purpose of these recommendations is to support clinicians' decision making, without taking out his/her autonomy when prescribing for an individual patient.

Entities:  

Keywords:  Ankylosing spondylitis; Guidelines; Meta-analysis; Nonsteroidal anti-inflammatory drugs; Spondyloarthritis; Systematic review

Year:  2021        PMID： 33468245     DOI： 10.1186/s42358-020-00160-6

Source DB:  PubMed          Journal:  Adv Rheumatol        ISSN： 2523-3106


  86 in total

1.  Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study.

Authors:  Ivette Essers; Carmen Stolwijk; Annelies Boonen; Marie L De Bruin; Marloes T Bazelier; Frank de Vries; Astrid van Tubergen
Journal:  Ann Rheum Dis       Date:  2014-10-31       Impact factor: 19.103

Review 2.  2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.

Authors:  Désirée van der Heijde; Sofia Ramiro; Robert Landewé; Xenofon Baraliakos; Filip Van den Bosch; Alexandre Sepriano; Andrea Regel; Adrian Ciurea; Hanne Dagfinrud; Maxime Dougados; Floris van Gaalen; Pál Géher; Irene van der Horst-Bruinsma; Robert D Inman; Merryn Jongkees; Uta Kiltz; Tore K Kvien; Pedro M Machado; Helena Marzo-Ortega; Anna Molto; Victoria Navarro-Compàn; Salih Ozgocmen; Fernando M Pimentel-Santos; John Reveille; Martin Rudwaleit; Jochen Sieper; Percival Sampaio-Barros; Dieter Wiek; Jürgen Braun
Journal:  Ann Rheum Dis       Date:  2017-01-13       Impact factor: 19.103

Review 3.  Review: Nonradiographic axial spondyloarthritis: new definition of an old disease?

Authors:  Joachim Sieper; Désirée van der Heijde
Journal:  Arthritis Rheum       Date:  2013-03

4.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

5.  [Efficiency and safety of different etoricoxib regimens in patients with axial spondyloarthritis, including ankylosing spondylitis].

Authors:  I Z Gaydukova; A P Rebrov
Journal:  Ter Arkh       Date:  2015       Impact factor: 0.467

6.  [Efficiency of different celecoxib regimens in patients with active axial spondyloarthritis: Results of the 4-week pilot open-label comparative single-center study 'AIM'].

Authors:  I Z Gaydukova; К A Gamayunova; K D Dorogoykina; A P Rebrov
Journal:  Ter Arkh       Date:  2017       Impact factor: 0.467

7.  The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; N Akkoc; J Brandt; C T Chou; M Dougados; F Huang; J Gu; Y Kirazli; F Van den Bosch; I Olivieri; E Roussou; S Scarpato; I J Sørensen; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2010-11-24       Impact factor: 19.103

8.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal.

Authors:  M Rudwaleit; R Landewé; D van der Heijde; J Listing; J Brandt; J Braun; R Burgos-Vargas; E Collantes-Estevez; J Davis; B Dijkmans; M Dougados; P Emery; I E van der Horst-Bruinsma; R Inman; M A Khan; M Leirisalo-Repo; S van der Linden; W P Maksymowych; H Mielants; I Olivieri; R Sturrock; K de Vlam; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

9.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

10.  The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis - 2019.

Authors:  Gustavo Gomes Resende; Eduardo de Souza Meirelles; Cláudia Diniz Lopes Marques; Adriano Chiereghin; Andre Marun Lyrio; Antônio Carlos Ximenes; Carla Gonçalves Saad; Célio Roberto Gonçalves; Charles Lubianca Kohem; Cláudia Goldenstein Schainberg; Cristiano Barbosa Campanholo; Júlio Silvio de Sousa Bueno Filho; Lenise Brandao Pieruccetti; Mauro Waldemar Keiserman; Michel Alexandre Yazbek; Penelope Esther Palominos; Rafaela Silva Guimarães Goncalves; Ricardo da Cruz Lage; Rodrigo Luppino Assad; Rubens Bonfiglioli; Sônia Maria Alvarenga Anti; Sueli Carneiro; Thauana Luíza Oliveira; Valderílio Feijó Azevedo; Washington Alves Bianchi; Wanderley Marques Bernardo; Marcelo de Medeiros Pinheiro; Percival Degrava Sampaio-Barros
Journal:  Adv Rheumatol       Date:  2020-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.